Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Camphor→

Camphor Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
76-22-2
Molecular formula
C10H16O
Molecular weight
152.23 g/mol
Drug class
Topical counterirritantterpene ketone used in external analgesic preparations
Mechanism of action
Produces a local cooling and counterirritant sensation through effects on transient receptor potential (TRP) channels in cutaneous sensory neurons. The perceived cooling and counterirritant response can transiently reduce awareness of superficial pain or itching.
Indications / reported uses
  • Temporary relief of minor muscle and joint aches when used in topical external analgesic products
  • Symptomatic relief of minor itching or irritation in selected topical formulations; do not apply to broken skin or use by ingestion

Sources: US eCFR — External analgesic drug products, 21 CFR Part 348 · PubChem — Camphor · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Camphor Environmental Risk Assessment (ERA) (the Camphor ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.